Tag
Eating difficulty is associated with broader functional vulnerability and cognitive decline, rather than directly triggering dementia, highlighting its importance in comprehensive geriatric assessment beyond dental health screening.
This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decl
This study illuminates how APOE ɛ4 accelerates executive function decline while ɛ2 may protect verbal episodic memory in individuals aged 90+, highlighting genetic influences on cognition in exceptional longevity.
This study links higher physical activity levels with slower cognitive and motor decline in Parkinson’s disease, highlighting the importance of sustained activity engagement.
This study demonstrates that arterial spin labeling spatial coefficient of variation (ASL-sCoV) correlates with cerebral small vessel disease burden and predicts cognitive decline over 11 years, outperforming traditional cerebral blood flow
This review synthesizes longitudinal evidence linking early adulthood vascular risks, particularly elevated systolic blood pressure and smoking, to midlife cognitive decline and brain structural alterations. It highlights critical intervent
Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managem
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
Brain-predicted age difference (brain-PAD) from MRI improves early dementia risk prediction in patients with subjective cognitive decline, outperforming traditional visual MRI ratings and offering prognostic value beyond amyloid biomarkers,
This study investigates whether recurrent hospitalizations mediate the association of postoperative delirium with long-term cognitive decline in seniors after major surgery, finding that rehospitalization does not significantly affect this
Higher parity in cognitively unimpaired postmenopausal women with positive β-amyloid status is linked to accelerated cognitive decline and hippocampal volume reduction, suggesting parity modulates resilience to Alzheimer’s pathology in prec
The POINTER Imaging study found no overall brain biomarker changes from a structured lifestyle intervention, but participants with lower baseline hippocampal volume showed greater cognitive benefit, suggesting imaging may help identify who
In the REGARDS cohort, prior myocardial infarction, including silent MI, was linked to faster long-term cognitive decline, suggesting heart attack history may help identify people at risk for future cognitive impairment.
A 24-month randomized trial found that exercise, intensive blood pressure and cholesterol control, or both together did not significantly improve cognitive function in older adults at increased risk for dementia.
In older adults with limited small vessel disease, “dirty-appearing” white matter on MRI was not linked to baseline cognition, cognitive decline, or dementia risk, unlike conventional white matter hyperintensities.
In two large U.S. cohorts, greater adherence to healthy dietary patterns—especially DASH—was associated with less subjective cognitive decline and slightly better objective cognition.
This longitudinal cohort study reveals that biomarker-based biological age, particularly KDMAge and PhenoAge residuals, significantly predicts progression of cerebral small vessel disease, including new lacunes and microbleeds, offering pot
A large-scale longitudinal study reveals that over 80% of community-dwelling older adults harbor mixed neuropathologies, identifying five distinct profiles that dictate specific cognitive decline trajectories, with ADNC and LATE-NC clusters
The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the
Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.
